Orphan drug development in China: progress and challenges
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference15 articles.
1. China Focus: China revises law to ensure drug safety;Shen;Xinhua,2019
2. Innovative measures to combat rare diseases in China: the national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research;Song;Intractable Rare Dis Res,2017
3. Challenges of rare diseases in China;Dong;Lancet,2016
4. China rare disease drug accessibility report and solution suggestion;Shao;China F D Ad Mag,2019
5. Rare diseases and legislation in China;Wang;Lancet,2010
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Orphan drug policy analysis in China;Frontiers in Pharmacology;2024-06-13
2. Governing cross-border healthcare in mainland China: a scoping review of national policies from 2002 to 2022;The Lancet Regional Health - Western Pacific;2024-04
3. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China;Therapeutic Innovation & Regulatory Science;2023-08-31
4. Epidemiological research on rare diseases using large-scale online search queries and reported case data;Orphanet Journal of Rare Diseases;2023-08-09
5. Estimating Rare Disease Incidences With Large-scale Internet Search Data: Development and Evaluation of a Two-step Machine Learning Method;JMIR Infodemiology;2023-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3